379 Epi-RTM P2 protocol produces a scalable polyclonal TIL product with a greater expansion success rate across hot and cold tumors in shorter culture time

• Benjamin Harris,
• Suman Vodnala,
• Yogin Patel,
• Gary Lee,
• Shobha Potluri,
• Melissa Bedard,
• Carson Harms,
• Melissa DeFrancesco,
• Jaewon Yun,
• Saeed Azimi,
• Ngoc-Han Ha,
• Audrey Garces

Affiliations

Benjamin Harris

Lyell Immunopharma, South San Francisco, CA, USA

Suman Vodnala

Lyell Immunopharma, South San Francisco, CA, USA

Yogin Patel

Lyell Immunopharma, South San Francisco, CA, USA

Gary Lee

Lyell Immunopharma, South San Francisco, CA, USA

Shobha Potluri

Lyell Immunopharma, South San Francisco, CA, USA

Melissa Bedard

Lyell Immunopharma, South San Francisco, CA, USA

Carson Harms

Lyell Immunopharma, South San Francisco, CA, USA

Melissa DeFrancesco

Lyell Immunopharma, South San Francisco, CA, USA

Jaewon Yun

Lyell Immunopharma, South San Francisco, CA, USA

Saeed Azimi

Lyell Immunopharma, South San Francisco, CA, USA

Ngoc-Han Ha

Lyell Immunopharma, South San Francisco, CA, USA

Audrey Garces

Lyell Immunopharma, South San Francisco, CA, USA